ALTEROLA BIOTECH INC.
ALTEROLA BIOTECH INC.
No insider data available
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||
Cash | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Funds Held Under Reinsurance Agreements Asset | - | - | - | - | - | - | - | 0 | - | - | 0 | 0 | |||||
Assets Current | |||||||||||||||||
Assets Current | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Value Added Tax Receivable | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Prepaid Expense Current | - | - | - | - | - | - | - | - | - | - | - | 0 | |||||
Deferred Income Tax Assets Net | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | - | - | |||||
Cash And Cash Equivalents At Carrying Value | 0 | 1 | - | - | - | - | - | - | - | - | - | - | |||||
Inventory Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | |||||
Assets Noncurrent | |||||||||||||||||
Deferred Offering Costs | - | 0 | - | - | - | - | - | - | - | - | - | - | |||||
Intangible Assets Current | 0 | - | - | - | 0 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | |||||
Deferred Costs | 0 | - | - | - | - | - | - | - | - | - | - | - | |||||
Assets | 1 | 1 | 0 | 0 | 0 | 13 | 12 | 12 | 12 | 12 | 12 | 12 | |||||
Liabilities And Stockhold… | |||||||||||||||||
Accrued Liabilities And Other Liabilities | - | - | - | - | - | - | - | - | - | - | - | 0 | |||||
Liabilities | |||||||||||||||||
Notes Payable | 2 | 1 | - | - | - | - | - | - | - | - | - | - | |||||
Convertible Notes Payable Current | 0 | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - | |||||
Liabilities Noncurrent | - | - | - | - | - | - | - | - | 0 | - | - | - | |||||
Accounts Payable Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Accrued Liabilities Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Liabilities Current | |||||||||||||||||
Liabilities Current | 4 | 2 | 1 | 1 | 3 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | |||||
Due To Related Parties Current And Noncurrent | - | - | - | - | - | - | - | 1 | 0 | 0 | 0 | 0 | |||||
Other Accrued Liabilities Current | - | 0 | - | - | - | - | - | - | - | - | - | - | |||||
Loans Payable Current | 0 | 0 | 0 | 0 | 2 | 1 | 1 | - | 0 | 0 | 0 | - | |||||
Liabilities | 4 | 2 | 1 | 1 | 3 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | |||||
Commitments And Contingencies | 0 | 0 | - | - | - | - | - | - | - | - | - | - | |||||
Preferred Stock Value | 0 | 0 | - | - | - | - | - | - | - | - | - | - | |||||
Common Stock Value | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Treasury Stock Common Value | - | - | - | - | 0 | - | - | - | - | - | - | - | |||||
Stockholders Equity | |||||||||||||||||
Additional Paid In Capital | 10 | 10 | 10 | 10 | 8 | 20 | 19 | 19 | 19 | 18 | 18 | 15 | |||||
Stockholders Equity | -2 | -1 | -1 | -1 | -2 | 10 | 10 | 10 | 11 | 11 | 11 | -1 | |||||
Retained Earnings Accumulated Deficit | -14 | -13 | -12 | -12 | -10 | -10 | -10 | -10 | -9 | -8 | -8 | -5 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | - | 0 | - | - | - | - | - | - | - | - | - | - | |||||
Accumulated Other Comprehensive Income Loss Foreig… | -0 | -0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | -0 | |||||
Minority Interest In Joint Ventures | - | -0 | - | - | - | - | - | - | - | - | - | - | |||||
Minority Interest | -0 | - | - | - | - | - | - | - | - | - | - | - | |||||
Liabilities And Stockholders Equity | 1 | 0 | 0 | 0 | 0 | 13 | 12 | 12 | 12 | 12 | 12 | 12 | |||||
Preferred Stock Par Or Stated Value Per Share | 0.001 | 0.001 | 0 | 0.001 | 0.001 | - | 0 | 0.001 | 0.001 | 0.001 | 0 | 0.001 | |||||
Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | - | 10 | 10 | 10 | 10 | 10 | 10 | |||||
Preferred Stock Shares Issued | 0 | 0 | - | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Par Or Stated Value Per Share | 0.001 | 0.001 | 0 | 0.001 | 0.001 | - | 0 | 0.001 | 0.001 | 0.001 | 0 | 0.001 | |||||
Common Stock Shares Authorized | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | - | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | |||||
Treasury Stock Common Shares | - | - | - | - | 29 | - | - | - | - | - | - | - | |||||
Common Stock Shares Issued | 1,467 | 1,467 | - | 1,383 | 1,556 | 1,614 | - | 1,614 | 1,614 | 1,605 | 1,605 | 1,573 | |||||
Shares Outstanding | 1,467 | 1,467 | 1,383 | 1,383 | 1,556 | 1,614 | 1,614 | 1,614 | 1,614 | 1,605 | 1,605 | 1,573 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -40.74% | 0.00% | -38.89% | -40.00% | -40.00% | -28.00% | -69.50% | -80.00% | -73.50% | 0.00% | -69.50% | -80.00% |
| 2023 | -43.64% | -13.45% | -43.64% | -45.67% | -55.22% | -64.18% | -23.28% | -1.64% | -42.62% | -23.33% | -58.33% | -25.83% |
| 2022 | -4.35% | -6.96% | -8.70% | -33.33% | -33.33% | -37.33% | 81.52% | 36.36% | 13.64% | -48.00% | -48.00% | -39.00% |
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 50+ calculated metrics
Subscribe to unlock 17+ years of data and 50+ calculated metrics
Performance and Valuation Metrics
Metrics | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liquidity Ratios | |||||||||||||||||
| Current Ratio | 0.32 | 0.29 | 0.00 | 0.00 | 0.08 | 0.10 | 0.02 | 0.11 | 0.14 | 0.11 | 0.12 | 0.07 | |||||
| Quick Ratio | 0.32 | 0.29 | 0.00 | 0.00 | 0.08 | 0.10 | 0.02 | 0.10 | 0.14 | 0.11 | 0.12 | 0.07 | |||||
| Working Capital | -2.47M | -1.72M | -1.33M | -1.35M | -2.32M | -2.10M | -2.08M | -1.63M | -1.12M | -957.04K | -909.50K | -1.13M | |||||
Leverage & Debt | |||||||||||||||||
| Debt to Equity | -1.61 | -1.63 | -1.00 | -1.00 | -1.21 | 0.23 | 0.23 | 0.19 | 0.13 | 0.11 | 0.11 | -1.83 | |||||
| Interest Coverage TTM | -6.25 | -5.20 | -4.91 | -7.71 | -6.03 | -62,641.34 | -68,627.89 | -110,817.84 | -170,293.00 | - | - | - | |||||
| Debt Ratio | 2.65 | 2.50 | 363.98 | 378.50 | 5.07 | 0.18 | 0.19 | 0.16 | 0.12 | 0.10 | 0.10 | 0.11 | |||||
Efficiency & Turnover | |||||||||||||||||
| Asset Turnover TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Per Share Metrics | |||||||||||||||||
| Free Cash Flow Per Share TTM | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | |||||
| Dividend Per Share TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Growth Metrics | |||||||||||||||||
| Net Income Growth (1Y) | 14.64% | -26.90% | -44.56% | -15.66% | -67.99% | -63.46% | -52.79% | 28.39% | 918.36% | 1,475.24% | 1,885.87% | 1,207.45% | |||||
| EPS Growth (1Y) | 21.56% | -19.60% | -35.29% | -1.54% | -66.80% | -81.83% | -53.05% | 25.09% | 861.24% | 1,380.34% | 1,877.08% | 1,196.78% | |||||
Valuation Metrics | |||||||||||||||||
| P/E TTM | -2.47 | -14.26 | -2.97 | -1.40 | -6.69 | -9.93 | -26.23 | -19.19 | -13.27 | -6.56 | -62.00 | -70.10 | |||||
| P/B TTM | -2.61 | -16.19 | -3.33 | -3.67 | -6.66 | 2.27 | 7.23 | 7.88 | 7.99 | 3.70 | 32.32 | -302.46 | |||||
| Market Cap | 5.87M | 24.21M | 4.42M | 4.98M | 13.85M | 23.08M | 70.54M | 80.70M | 85.87M | 41.74M | 353.16M | 229.60M | |||||
| Enterprise Value | 8.14M | 25.31M | 4.57M | 5.22M | 15.39M | 24.42M | 71.94M | 80.84M | 86.07M | 41.90M | 353.36M | 229.56M | |||||
Calculated Values | |||||||||||||||||
| Free Cash Flow TTM | -1.45M | -832.24K | -576.98K | -654.16K | -1.31M | -945.91K | -1.47M | 1.32M | 44.34K | 82.56K | 297.97K | -2.34M | |||||
| Net Debt | 2.27M | 1.10M | 142.95K | 241.49K | 1.54M | 1.34M | 1.40M | 138.44K | 197.50K | 165.07K | 198.87K | -40.11K | |||||
Per-Share and Margin | |||||||||||||||||
| EPS TTM | |||||||||||||||||
| Adjusted EPS TTM | |||||||||||||||||
| Cash Flow Per Share TTM | |||||||||||||||||
| Pretax Margin TTM | |||||||||||||||||
| Stock Comp to Revenue TTM | |||||||||||||||||
Turnover Ratios and Averages | |||||||||||||||||
| Average Assets | |||||||||||||||||
| Average Equity | |||||||||||||||||
| Average Inventory | |||||||||||||||||
| Average Receivables | |||||||||||||||||
| Average Accounts Payables | |||||||||||||||||
| Inventory Turnover TTM | |||||||||||||||||
| Payables Turnover TTM | |||||||||||||||||
| Days Inventory Outstanding TTM | |||||||||||||||||
| Days Payables Outstanding TTM | |||||||||||||||||
| Cash Conversion Cycle TTM | |||||||||||||||||
| Working Capital to Revenue | |||||||||||||||||
| Deferred Revenue to Revenue | |||||||||||||||||
Growth Rates | |||||||||||||||||
| Total Assets Growth (1Y) | |||||||||||||||||
| Total Assets Growth (3Y) | |||||||||||||||||
| Total Assets Growth (5Y) | |||||||||||||||||
| Dividends Paid Growth (1Y) | |||||||||||||||||
| Dividends Paid Growth (3Y) | |||||||||||||||||
| Dividends Paid Growth (5Y) | |||||||||||||||||
| EPS Growth (3Y) | |||||||||||||||||
| EPS Growth (5Y) | |||||||||||||||||
| Net Income Growth (3Y) | |||||||||||||||||
| Net Income Growth (5Y) | |||||||||||||||||
| Net Profit Margin Growth (1Y) | |||||||||||||||||
| Net Profit Margin Growth (3Y) | |||||||||||||||||
| Net Profit Margin Growth (5Y) | |||||||||||||||||
| Net Revenue Growth (3Y) | |||||||||||||||||
| Net Revenue Growth (5Y) | |||||||||||||||||
| Deferred Revenue Growth (1Y) | |||||||||||||||||
| Retained Earnings Growth (1Y) | |||||||||||||||||
Credit, Liquidity, Returns, Payout | |||||||||||||||||
| Cash Ratio | |||||||||||||||||
| Net Working Capital | |||||||||||||||||
| Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to Equity | |||||||||||||||||
| Altman A | |||||||||||||||||
| Altman B | |||||||||||||||||
| Altman C | |||||||||||||||||
| Altman D | |||||||||||||||||
| Altman E | |||||||||||||||||
| Altman Z-Score | |||||||||||||||||
| ROA TTM | |||||||||||||||||
| ROE TTM | |||||||||||||||||
| NOPAT TTM | |||||||||||||||||
| ROIC TTM | |||||||||||||||||
| Effective Tax Rate TTM | |||||||||||||||||
| Payout Ratio TTM | |||||||||||||||||
| Dilution Ratio | |||||||||||||||||
| Retained Earnings to Equity | |||||||||||||||||
| Treasury Stock to Equity | |||||||||||||||||
| Treasury Stock Change (1Y) | |||||||||||||||||
| Accrued to Current Liabilities | |||||||||||||||||
Valuation Ratios | |||||||||||||||||
| P/CF TTM | |||||||||||||||||
| Dividend Yield TTM | |||||||||||||||||
| Free Cash Flow Yield TTM | |||||||||||||||||
| EV EBITDA TTM | |||||||||||||||||
| EV EBIT TTM | |||||||||||||||||
| Stock Compensation TTM | |||||||||||||||||
| Adjusted Net Income TTM | |||||||||||||||||
| Billings TTM | |||||||||||||||||
| Total Debt | |||||||||||||||||
| Invested Capital | |||||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
ALTEROLA BIOTECH INC. (ABTI) — SEC Financial Statements & Analysis
ALTEROLA BIOTECH INC. (ABTI) is a medicinal chemicals & botanical products company. ALTEROLA BIOTECH INC. trades on ABTI: OTC as: ABTI. Based on its latest SEC filing (Form 10-Q, period ending 2024-09-30), ALTEROLA BIOTECH INC. reported a Debt-to-Equity ratio of -1.61x, a Price-to-Book (P/B) ratio of -2.61 (TTM), at a market cap of $5.87M. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- -1.61x
- P/B TTM
- -2.61
- Market Cap
- $5.87M
Data as of 2024-09-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is ALTEROLA BIOTECH INC. in?
ALTEROLA BIOTECH INC. (ABTI) operates in the Medicinal Chemicals & Botanical Products industry.
What is ABTI's market cap?
ALTEROLA BIOTECH INC. (ABTI) has a market capitalization of $5.87M as of 2024-09-30.
What exchange does ABTI trade on?
ALTEROLA BIOTECH INC. (ABTI) trades on the ABTI: OTC.